APO-DAPAGLIFLOZIN-METFORMIN TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Предлага се от:

APOTEX INC

АТС код:

A10BD15

INN (Международно Name):

METFORMIN AND DAPAGLIFLOZIN

дозиране:

5MG; 1000MG

Лекарствена форма:

TABLET

Композиция:

DAPAGLIFLOZIN 5MG; METFORMIN HYDROCHLORIDE 1000MG

Начин на приложение:

ORAL

Броя в опаковка:

15G/50G

Вид предписание :

Prescription

Каталог на резюме:

Active ingredient group (AIG) number: 0257650002; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2023-05-16

Данни за продукта

_APO-DAPAGLIFLOZIN-METFORMIN (dapagliflozin and metformin
hydrochloride tablets) _
_Page 1 of 85 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
APO-DAPAGLIFLOZIN-METFORMIN
Dapagliflozin and Metformin Hydrochloride tablets
Tablets, 5 mg dapagliflozin / 850 mg metformin hydrochloride,
5 mg dapagliflozin / 1000 mg metformin hydrochloride,
for oral use
Combination of oral blood glucose lowering drugs
Apotex Inc.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
MAY 16, 2023
Date of Revision:
SEP 19, 2023
Submission Control Number: 275438
_APO-DAPAGLIFLOZIN-METFORMIN (dapagliflozin and metformin
hydrochloride tablets) _
_Page 2 of 85 _
RECENT MAJOR LABEL CHANGES
1. INDICATIONS. 1.2 Geriatrics
09/2023
2 CONTRAINDICATIONS
09/2023
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
09/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and
Dosage Adjustment
09/2023
4 DOSAGE AND ADMINISTRATION, 4.4 Administration
09/2023
7 WARNINGS AND PRECAUTIONS, Driving and Operating Machinery
09/2023
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
09/2023
7 WARNINGS AND PRECAUTIONS, Hematologic
09/2023
7 WARNINGS AND PRECAUTIONS,
Hepatic/Biliary/Pancreatic
09/2023
7 WARNINGS AND PRECAUTIONS,
Monitoring and Laboratory Tests
09/2023
7 WARNINGS AND PRECAUTIONS,
Neurologic
09/2023
7 WARNINGS AND PRECAUTIONS,
Renal
09/2023
7.1.4 Geriatrics
09/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
5
1
INDICATIONS
................................................................................................................
5
1.1
Pediatrics
....................................